Aibin Liang

3.1k total citations
117 papers, 1.5k citations indexed

About

Aibin Liang is a scholar working on Oncology, Molecular Biology and Hematology. According to data from OpenAlex, Aibin Liang has authored 117 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 57 papers in Oncology, 45 papers in Molecular Biology and 26 papers in Hematology. Recurrent topics in Aibin Liang's work include CAR-T cell therapy research (44 papers), Acute Myeloid Leukemia Research (19 papers) and Lymphoma Diagnosis and Treatment (19 papers). Aibin Liang is often cited by papers focused on CAR-T cell therapy research (44 papers), Acute Myeloid Leukemia Research (19 papers) and Lymphoma Diagnosis and Treatment (19 papers). Aibin Liang collaborates with scholars based in China, United States and Thailand. Aibin Liang's co-authors include Wenjun Zhang, Yu Fang, Yao Sun, Junjun Liu, Jianhua Yang, Beizhan Jiang, Guo‐Tong Xu, Bing Xiu, Ping Li and Wenbin Qian and has published in prestigious journals such as Advanced Materials, Nature Communications and Journal of Clinical Oncology.

In The Last Decade

Aibin Liang

104 papers receiving 1.5k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Aibin Liang China	19	689	498	247	202	182	117	1.5k
Deepa S. Subramaniam United States	25	810 1.2×	922 1.9×	252 1.0×	205 1.0×	378 2.1×	81	2.2k
Felix Bachmann Switzerland	18	797 1.2×	341 0.7×	138 0.6×	218 1.1×	206 1.1×	60	1.7k
Hajime Okita Japan	25	1.2k 1.8×	349 0.7×	163 0.7×	199 1.0×	200 1.1×	124	2.2k
Peter Nørgaard Denmark	23	707 1.0×	785 1.6×	254 1.0×	195 1.0×	135 0.7×	78	1.6k
Anna Sebestyén Hungary	22	1.1k 1.6×	464 0.9×	153 0.6×	269 1.3×	518 2.8×	103	1.9k
Jin Ding China	22	465 0.7×	439 0.9×	163 0.7×	489 2.4×	173 1.0×	83	1.6k
Peng Xu China	22	899 1.3×	760 1.5×	136 0.6×	392 1.9×	178 1.0×	117	2.0k
Frank Griscelli France	21	969 1.4×	361 0.7×	117 0.5×	121 0.6×	438 2.4×	73	1.6k
Jens Hasskarl United States	20	587 0.9×	503 1.0×	75 0.3×	122 0.6×	146 0.8×	42	1.2k
Karen M. Helm United States	22	396 0.6×	254 0.5×	233 0.9×	237 1.2×	111 0.6×	35	1.3k

Countries citing papers authored by Aibin Liang

Since Specialization

Citations

This map shows the geographic impact of Aibin Liang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Aibin Liang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Aibin Liang more than expected).

Fields of papers citing papers by Aibin Liang

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Aibin Liang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Aibin Liang. The network helps show where Aibin Liang may publish in the future.

Co-authorship network of co-authors of Aibin Liang

This figure shows the co-authorship network connecting the top 25 collaborators of Aibin Liang. A scholar is included among the top collaborators of Aibin Liang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Aibin Liang. Aibin Liang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Lei, Wen, Wenhai Deng, Wenxia Gao, et al.. (2025). Safety and feasibility of 4-1BB co-stimulated CD19-specific CAR-NK cell therapy in refractory/relapsed large B cell lymphoma: a phase 1 trial. Nature Cancer. 6(5). 786–800. 14 indexed citations

Ni, Ying, et al.. (2025). Upregulation of CD19 by low‐dose chidamide promotes CAR T cells functionality in B-cell non-Hodgkin lymphoma. Discover Oncology. 16(1). 84–84. 1 indexed citations

Chen, Xi, Yifan Liu, Wenjun Zhang, et al.. (2025). Sequential PD-1 inhibitors as consolidative therapy post-CD19 CART in relapsed/refractory NHL: a propensity score matching cohort study. Journal of Translational Medicine. 23(1). 1247–1247.

Wang, Xiangmin, Qing Zhang, Hongyuan Zhou, et al.. (2024). Impact of tocilizumab on anti‐CD19 chimeric antigen receptor T‐cell therapy in B‐cell acute lymphoblastic leukemia. Cancer. 130(15). 2660–2669. 3 indexed citations

Li, Ping, Aijun Shen, Yan Lu, et al.. (2024). Indicators describing the tumor lesion aggregation and dissemination and their impact on the prognosis of patients with diffuse large B cell lymphoma receiving chimeric antigen receptor T cell therapy. Cancer Medicine. 13(6). e6991–e6991. 3 indexed citations

Shi, Rongyi, Neng Zhou, Xuan Li, et al.. (2024). Trafficking circuit of CD8+ T cells between the intestine and bone marrow governs antitumour immunity. Nature Cell Biology. 26(8). 1346–1358. 4 indexed citations

Xie, Li, Chiqi Chen, Wenqian Yang, et al.. (2024). LILRB4 regulates multiple myeloma development through STAT3-PFKFB1 pathway. Cell Death and Disease. 15(7). 515–515. 9 indexed citations

Yu, Fangfang, Jianmin Yang, Siguo Hao, et al.. (2024). Optimal timing and impact of allogeneic peripheral blood stem cell transplantation in adult T-cell lymphoblastic lymphoma: insights from a large cohort multi-center real-world study in Shanghai. Bone Marrow Transplantation. 60(3). 380–388.

Hao, Yuanyuan, Panpan Chen, Mengyuan Li, et al.. (2023). Tumor-derived exosomes induce initial activation by exosomal CD19 antigen but impair the function of CD19-specific CAR T-cells via TGF-β signaling. Frontiers of Medicine. 18(1). 128–146. 11 indexed citations

10.

Lu, Yan, et al.. (2023). [Efficacy and safety analysis of the zanubrutinib-based bridging regimen in chimeric antigen receptor T-cell therapy for relapsed/refractory diffuse large B-cell lymphoma].. PubMed. 44(10). 813–819. 3 indexed citations

11.

Zhou, Lili, et al.. (2023). The Efficacy and Safety of Decitabine Combined with Fludarabine and Cyclophosphamide As Conditioning Regimen in Second CD19 CAR-T Infusion. Blood. 142(Supplement 1). 6882–6882.

12.

Zhou, Hang, et al.. (2023). CAR‐Aptamers Enable Traceless Enrichment and Monitoring of CAR‐Positive Cells and Overcome Tumor Immune Escape. Advanced Science. 11(10). e2305566–e2305566. 9 indexed citations

13.

Qian, Wenbin, et al.. (2023). Challenges and optimal strategies of CAR T therapy for hematological malignancies. Chinese Medical Journal. 136(3). 269–279. 12 indexed citations

14.

Chen, Panpan, Yao Liu, Ying Lu, et al.. (2023). Outcomes and risk factors of SARS‐CoV‐2 omicron variant in B‐cell lymphoma patients following CD19 targeted CAR‐T therapy. Cancer Medicine. 12(22). 20838–20846. 2 indexed citations

15.

Li, Ping, Wei Liu, Lili Zhou, et al.. (2023). Two-Year Follow-up Results of C-CAR066, a Novel Anti-CD20 Chimeric Antigen Receptor Cell Therapy (CAR-T) in Relapsed or Refractory (r/r) Large B-Cell Lymphoma (LBCL) Patients after Failure of CD19 CAR-T Therapy. Blood. 142(Supplement 1). 2115–2115. 2 indexed citations

16.

Tian, Xiaoxue, et al.. (2022). Inhibition of DEK Enhances Doxorubicin-Induced Apoptosis and Cell Cycle Arrest in T-Cell Acute Lymphoblastic Leukemia Cells. Disease Markers. 2022. 1–10. 1 indexed citations

17.

Li, Xiaolei, Hanren Dai, Xian Li, et al.. (2021). Optimal model establishment of whole-process management data for CAR-T therapy in China—how should this be done?. Cellular and Molecular Immunology. 19(1). 122–124. 1 indexed citations

18.

Zhou, Jie, Cheng Guo, Hao Wu, et al.. (2021). Dnmt3a is downregulated by Stat5a and mediates G0/G1 arrest by suppressing the miR-17-5p/Cdkn1a axis in Jak2V617F cells. BMC Cancer. 21(1). 1213–1213. 5 indexed citations

19.

Chen, Yaoyu, Yi Shan, Min Lü, et al.. (2016). Alox5 Blockade Eradicates JAK2V617F -Induced Polycythemia Vera in Mice. Cancer Research. 77(1). 164–174. 10 indexed citations

20.

Xiu, Bing, et al.. (2013). Genetic inhibition of vascular endothelial growth factor receptor-1 significantly inhibits the migration and proliferation of leukemia cells and increases their sensitivity to chemotherapy. Oncology Reports. 29(5). 2030–2038. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact